

**SECTION 1. LEGISLATIVE MANAGEMENT STUDY – PRESCRIPTION DRUG COUPON AND FINANCIAL ASSISTANCE PROGRAM UTILIZATION**

During the 2023-2024 interim, the legislative management shall consider studying the prevalence and usage of third-party payments to reduce or eliminate North Dakota patients' cost-sharing and out-of-pocket costs for prescription drugs, including programs offered by the manufacturer of a prescription drug. The study shall include the prevalence and usage of third-party payments, including by the manufacturer of a prescription drug, in the North Dakota commercial insurance market, government programs, the availability of such programs to uninsured North Dakotans, eligibility criteria, and the impact of these programs on health care costs and prescription drug pricing.

In conducting the study, input shall be received from the following, but not limited to, groups: health insurance carriers, patients or patient groups, prescription drug manufacturers, pharmacy benefit managers, pharmacies or pharmacy association representatives, government and independent academic sources, and any other stakeholder with relevant information to the study. Participants shall disclose any ties or financial compensation received by any entities in the prescription drug supply chain.

The legislative management shall report its findings and recommendations, together with any legislation required to implement the recommendations, to the sixty-ninth legislative assembly.